Description: Cell Source, Inc., a biotechnology company, develops cell therapy treatments. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, such as treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. The company was founded in 2011 and is headquartered in New York, New York.
Home Page: www.cell-source.com
57 West 57th Street
New York,
NY
10019
United States
Phone:
646 416 7896
Officers
| Name | Title |
|---|---|
| Mr. Itamar Shimrat | CEO, Pres & CFO |
| Dr. Dennis M. Brown B.Sc., M.A., Ph.D. | Exec. Chairman |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 1 |